• AcroMetrix (Benicia, California) said that it has received FDA clearance for the VeriSure Pro HBV DNA external quality control. This control is for use on Chiron’s procleix ultrio assay for the detection of HBV DNA using nucleic acid amplification. AcroMetrix is the only Chiron approved provider of controls for the Chiron Procleix and Ultrio assays. The VeriSure Pro line of external quality controls is intended to provide a means of estimating accuracy and detecting systematic deviations of nucleic acid test procedures for the qualitative determination of HIV-1 RNA, HBV DNA, HCV RNA, and WNV RNA. AcroMetrix makes products for clinical diagnostic and blood testing laboratories.

• PrimeHoldings.Com (Salt Lake City) reported that MindPix has added three new UltraFlex products to serve the needs of the outpatient rehabilitation market estimated at $11.5 billion dollars in 2005. The new products complete a line of rehabilitation devices utilizing resistance and strength training. UltraFlex now has a total of five rehabilitation and performance enhancement devices offering a complete and unique solution to outpatient rehabilitation market. PrimeHoldings.com is a holding company with initiatives in telecommunications and other strategic industries.

• Sono-Tek (Milton, New York) reported the release of the MediCoat PSI. The MediCoat PSI offers the same stent coating features as the MediCoat DES systems used for coating cardiac stents. The new PSI model is ideal for coating large peripheral stents, and it is capable of coating, in one cycle, multiple stents up to a cumulative length of 8 inches. MediCoat PSI incorporates Sono-Tek’s MicroMist ultrasonic atomizing nozzle, and provides stent motion that assures complete coverage of large vascular stents. Sono-Tek makes liquid spray products based on its ultrasonic nozzle technology.

• Teleflex Medical (Research Triangle Park, North Carolina) reported the launch of the Bravo nasal pillow mask for use with sleep therapy systems in the treatment of obstructive sleep apnea. The ergonomic design of the Bravo produces a higher level of comfort for the sleep apnea patient, promoting greater acceptance and compliance. The Bravo joins Teleflex Medical’s existing family of Hybrid and Nasal-Aire II sleep therapy interfaces. The Hybrid interface is designed to be a universal interface for patients, clinicians and providers. The Hybrid serves as a nasal interface, an oral interface, and a combination of the two. Its proprietary design enhances patient comfort and compliance by eliminating pressure points on the forehead and across the bridge of the nose. Teleflex Medical, a division of Teleflex Incorporated, makes disposable medical products, surgical instruments and medical devices.

No Comments